Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 06:00 ET | Source: Ring Therapeutics

Ring Therapeutics Presents New Data on its AnelloBricks® Manufacturing Platform at the 28th Annual American Society of Gene & Cell Therapy Conference

AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic advantages in manufacturing scalability and cost compared to existing vector...
November 04, 2024 21:00 ET | Source: Ring Therapeutics

Ring Therapeutics Announces New Strategic Partnerships with A*STAR and SERI to Establish Gene Therapy R&D Efforts in Singapore, a Growing Global Biotech Hub

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...
October 22, 2024 02:00 ET | Source: Ring Therapeutics

Ring Therapeutics Presents Preclinical Data on Anellogy™ Platform at the 31st Annual European Society of Gene & Cell Therapy Conference

- Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirus CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ring...
October 08, 2024 08:00 ET | Source: Ring Therapeutics

Ring Therapeutics to Present Opening Keynote Lecture at the 19th International Symposium on Preparative and Industrial Chromatography and Allied Techniques (SPICA) Conference

CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize genetic medicines with its commensal virome platform,...
May 07, 2024 06:00 ET | Source: Ring Therapeutics

Ring Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy Conference

Expanded payload capacity of Anellovectors widens the therapeutic potential of this novel class of viral vectors Data showcasing transduction and redosability of Anellovectors in non-human primates...
April 22, 2024 16:32 ET | Source: Ring Therapeutics

Ring Therapeutics Announces Presentations at the 27th Annual American Society of Gene and Cell Therapy

Development of a new class of viral vectors – Anellovectors – with potential to deliver DNA payloads across broad tissue types in redosable manner Anellovectors demonstrate expanded payload capacity...
April 01, 2024 08:00 ET | Source: Ring Therapeutics

Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus

– Publication describes the first gene delivery vector system based on a human commensal virus, the anellovirus – – Development of the Self-Amplifying Trans-complementation of a Universal Recombinant...
October 24, 2023 08:00 ET | Source: Ring Therapeutics

Ring Therapeutics Presents New Data on Anellogy™ Platform at the 30th Annual European Society of Gene & Cell Therapy Congress

Translation of innate properties of anelloviruses to create Anellovectors with strengthened tropism and immune stealth, enabling redosability Transduction and expression across a variety of tissues...
September 26, 2023 08:00 ET | Source: Ring Therapeutics

Ring Therapeutics Announces Two Late Breaker Presentations at the 30th Annual European Society of Gene & Cell Therapy Conference

Ring to present new data on its Anellogy™ platform The first new class of viral vector in decades - Robust transduction of a variety of cell and tissue types achieved by AnelloVectors Development of...
June 07, 2023 08:00 ET | Source: Ring Therapeutics

Ring Therapeutics Announces Appointment of Bioprocess and Biomanufacturing Veteran Konstantin Konstantinov, Ph.D. as Chief Technology Officer

CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...